Identifier	Drug Name	SMILES	Evidence	Experimental evidence	MoA code	Potential MoA	Annotator	Reference	Reference (2)	Reference (3)	Reference (4)
cov001	Mesalazine	C1=CC(=C(C=C1N)C(=O)O)O	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	5	Immunomodulatory	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov002	Toremifene	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	2	Viral entry	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov003	Eplerenone	C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	5	Immunomodulatory	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov004	Paroxetine	C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov005	Sirolimus	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	1	Host factor	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov006	Dactinomycin	C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov007	Ibesartan	[2H]C1=C(C(=C(C(=C1CN2C(=NC3(C2=O)CCCC3)CCCC)[2H])[2H])C4=CC=CC=C4C5=NNN=N5)[2H]	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	2	Viral entry	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov008	Mercaptopurine	C1=NC2=C(N1)C(=S)N=CN2	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	5	Immunomodulatory	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov009	Melatonin	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	5	Immunomodulatory	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov010	Quinacrine	CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC	3	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	2	Viral entry	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov011	Carvedilol	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	5	Immunomodulatory	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov012	Colchicine	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov013	Camphor	CC1(C2CCC1(C(=O)C2)C)C	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	2	Viral entry	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov014	Equilin	C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	2	Viral entry	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov015	Oxymetholone	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov016	Emodin	CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O	1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov017	Sirolimus + Dactinomycin		1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov018	Toremifene + Emodin		1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov019	Mercaptopurine + Melatonin		1	None, it´s a computational repurposing strategy based on PPI networks (human and host-pathogen) and CoV-induced transcriptional changes. However, several of the drugs proposed have shown some level of effectiveness against other human viruses (Table 1).	0	Unknown	Patrick	https://www.nature.com/articles/s41421-020-0153-3			
cov020	6-fluoro-3-hydroxy-2-pyrazinecarboxamide	C1=C(N=C(C(=O)N1)C(=O)N)F	4	Developed as antiinfluenza	4	RNA transcription or replication	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/28769016	https://www.dailysabah.com/life/health/japanese-drug-favipiravir-proving-effective-against-covid-19-in-as-little-as-4-days		
cov021	GS-5734	CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4	4	Decreases monkey infection by MERS-CoV	4	RNA transcription or replication	Miquel/Gemma	https://www.pnas.org/content/early/2020/02/12/1922083117	https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR1DeWaS1w2LD3MrW		
cov022	Toremifene citrate	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3	2	Effective against SARS-CoV MERS-CoV in vitro / inhibits EVOB entry in cells / identified in network screening	2	Viral entry	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/	https://stm.sciencemag.org/content/5/190/190ra79	https://www.nature.com/articles/s41421-020-0153-3	
cov023	Chloroquine diphosphate	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O	4	Anti SARS-CoV and MERS-CoV in vitro	2	Viral entry	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071	https://www.sciencedirect.com/science/article/pii/S0883944120303907	https://www.ncbi.nlm.nih.gov/pubmed/32074550	
cov024	Loperamide	CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4	2	Anti SARS-CoV and MERS-CoV in vitro	0	Unknown	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733787/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/		
cov025	Used for MERS clinically / No effect in clinical trial for Covid19	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O	-1	Anti SARS-CoV and MERS-CoV in vitro / NO EFFECT IN CLINICAL TRIAL	0	Unknown	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/	https://www.nejm.org/doi/full/10.1056/NEJMoa2001282		
cov026	Chlorpromazine hydrochloride	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl	2	Effective against SARS-CoV and MERS-CoV in vitro	2	Viral entry	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136071/		
cov027	Triflupromazine hydrochloride	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F	2	Effective against SARS-CoV and MERS-CoV in vitro	2	Viral entry	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/			
cov028	Imatinib mesylate	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O	2	Effective against SARS-CoV and MERS-CoV in vitro	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/	https://jvi.asm.org/content/90/19/8924		
cov029	Dasatinib	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	2	Effective against SARS-CoV and MERS-CoV in vitro	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/			
cov030	Gemcitabine hydrochloride	C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F.Cl	2	Effective against SARS-CoV and MERS-CoV in vitro	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/			
cov031	Equilin	C[C@]12CC[C@H]3C(=CCC4=C3C=CC(=C4)O)[C@@H]1CCC2=O	2	inhibits EVOB entry in cells / identified in network screening	2	Viral entry	Miquel/Gemma	https://stm.sciencemag.org/content/5/190/190ra79	https://www.nature.com/articles/s41421-020-0153-3		
cov032	Irbesartan	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5	2	identified in network screening	2	Viral entry	Miquel/Gemma	https://www.nature.com/articles/s41421-020-0153-3			
cov033	Sirolimus	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC	3	MERS-CoV 60% decreased infection in vitro / improved clinical outcome H1N1	5	Immunomodulatory	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733787	https://www.ncbi.nlm.nih.gov/pubmed/24105455		
cov034	Melatonin	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC	2	Prolongs survival due to anti inflammation (not virus related)	5	Immunomodulatory	Miquel/Gemma	https://www.nature.com/articles/s41421-020-0153-3			
cov035	Eplerenone	C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC	2	Prolongs survival, tested in viral myocarditis in mice	5	Immunomodulatory	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/19213804			
cov036	Teicoplanin	CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O	2	Blocks cell entry of Covid-19 in vitro	2	Viral entry	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.02.05.935387v1.abstract	https://www.ncbi.nlm.nih.gov/pubmed/30170320		
cov037	Ribavirin	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N	4	Combined with IFNalpha improves MERS-Cov	4	RNA transcription or replication	Miquel/Gemma	https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)70920-X/fulltext			
cov038	Penciclovir	C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N	3	Used in Herpex treatment	4	RNA transcription or replication	Miquel/Gemma	https://pubchem.ncbi.nlm.nih.gov/compound/Penciclovir			
cov039	Galidesivir	C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O	2	High efficacy in vitro for filoviruses, under clinical trials	4	RNA transcription or replication	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/24590073			
cov040	Disulfiram	CCN(CC)C(=S)SSC(=S)N(CC)CC	2	In vitro inhibition of SARS and MERS enzymes	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/29289665			
cov041	Ritonavir	CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O	-1	Used for MERS clinically / No effect in clinical trial for Covid19	3	Protease inhibitor	Miquel/Gemma	https://www.nejm.org/doi/full/10.1056/NEJMoa2001282	https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3846-x	https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1	https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v2
cov042	Darunavir	CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	3	Not clear if clinical trial ongoing	3	Protease inhibitor	Miquel/Gemma	https://www.pharmaceutical-technology.com/news/jj-janssen-darunavir-coronavirus/			
cov043	Favilavir	C1=C(N=C(C(=O)N1)C(=O)N)F	4		4	RNA transcription or replication	Miquel/Gemma	https://www.upi.com/Health_News/2020/02/17/China-approves-antiviral-favilavir-to-treat-coronavirus/5291581953892/			
cov044	Oseltamivir	CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC	4	Ongoing trial, used for influenza A and B	0	Unknown	Miquel/Gemma	https://laegemiddelstyrelsen.dk/da/nyheder/temaer/ny-coronavirus-covid-19/~/media/5B83D25935DF43A38FF823E24604AC36.ashx			
cov045	ASC09F		4	Ongoing trial in combination with oseltamivir	3	Protease inhibitor	Miquel/Gemma				
cov046	Nafamostat	C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N	2	potent inhibitor of MERS-CoV, which prevents membrane fusion	2	Viral entry	Miquel/Gemma	https://www.nature.com/articles/s41422-020-0282-0			
cov047	Griffithsin		2	Effective in vitro and in vivo against SARS	2	Viral entry	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/20032190	https://www.ncbi.nlm.nih.gov/pubmed/24145548		
cov048	Resveratrol	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O	2	In principle inhibits MERS infection...	0	Unknown	Miquel/Gemma	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2253-8			
cov049	Umifenovir	CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3	4	Used in influenza treatment, only approved in Russia, clinical assays for COVID 19 ongoing	2	Viral entry	Miquel/Gemma	https://pubmed.ncbi.nlm.nih.gov/15266832/			
cov050	Mefloquine	C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O	3	Effective against MERS and SARS in vitro	0	Unknown	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/			
cov051	Amodiaquine	CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O	3	Effective against MERS and SARS in vitro / used in EBOLa	0	Unknown	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136000/	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934550/		
cov052	Ifenprodil (maybe enters clinical trial)	CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3	4	Improves survival of H5N1 infected mice	5	Immunomodulatory	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/31822599			
cov053	TMPRSS2 inhibitor (not disclosed)		2	effectively blocks cell entry of COVID19	2	Viral entry	Miquel/Gemma	https://www.sciencedirect.com/science/article/pii/S0092867420302294			
cov054	6'-Fluorinated Aristeromycin Analog		2	Broad spectrum in vitro against RNA viruses	4	RNA transcription or replication	Miquel/Gemma	https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00781			
cov055	Acyclovir Fleximer analogues		2	In vitro effective against MERS	4	RNA transcription or replication	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/26048809			
cov056	Thiopurine analogues		2	In vitro inhibition of MERS PLp	3	Protease inhibitor	Miquel/Gemma	https://www.sciencedirect.com/science/article/pii/S0166354214003623			
cov057	Compound 6		2	In vitro inhibition of MERS PLp	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/30940566			
cov058	GC376	CC(C)C[C@@H](C(=O)N[C@@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2=CC=CC=C2.[Na+]	2	Cures a coronavirus-like disease in felines	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/27027316			
cov059	GC813		2	Computer based design of MERS 3CLpro inhibitor	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891363/			
cov060	Phenylisoserine inhibitors		2	Computer based design of SARS 3CLpro inhibitor	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/28454669			
cov061	Peptidomimetic inhibitors		2	Antiviral effect in vitro against SARS and MERS	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/28216367			
cov062	1,2,3-triazoles		2	Computer based design of SARS 3CLpro inhibitor	3	Protease inhibitor	Miquel/Gemma	https://www.sciencedirect.com/science/article/pii/S0960894X18307509			
cov063	Neuraminidase inhibitor analogues		2	Computer based design of SARS 3CLpro inhibitor	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/27240464			
cov064	Unsymmetric aromatic disulfides		2	In vitro inhibition of SARS Mpro	3	Protease inhibitor	Miquel/Gemma	https://www.sciencedirect.com/science/article/pii/S0223523417304063			
cov065	Pyrithiobac derivatives		2	In vitro inhibition of SARS Mpro, they derive from herbicides	3	Protease inhibitor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/30784880			
cov066	2,6-Bis-arylmethyloxy-5-hydroxychromones		2	In vitro validation against SARS enzymes	4	RNA transcription or replication	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/21925774			
cov067	SSYA10-001	ON(=O)C1=C(SCC2=NNC(=S)N2CC=C)C=CC=C1	2	In vitro validation against SARS and MERS	4	RNA transcription or replication	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136041/			
cov068	Triazol derivatives		2	FRET against MERS enzyme	4	RNA transcription or replication	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/31955138			
cov069	Nitazoxanide	CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]	4	Induces interferon production, works in influenza	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/25108173			
cov070	Recombinant interferons		1		5	Immunomodulatory	Miquel/Gemma				
cov071	Cyclosporine A	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	3	Reduces MERS infection in human in vitro ex vivo	5	Immunomodulatory	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/29772254	https://www.ncbi.nlm.nih.gov/pubmed/23620378		
cov072	Alisporivir	CC[C@H]1C(=O)N([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C(C)C)CC)C)C	3	Prevents in vitro MERS/SARS infection but not in mouse model	0	Unknown	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/27840112			
cov073	Selumetinib	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO	2	Inhibits MERS replication in vitro	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/25487801			
cov074	Trametinib	CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5	2	Inhibits MERS replication in vitro	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/25487801			
cov075	Rapamycin	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC	2	Inhibits MERS replication in vitro	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/25487801			
cov076	Saracatinib	CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl	2	Inhibits MERS replication in vitro	1	Host factor	Miquel/Gemma	https://www.ncbi.nlm.nih.gov/pubmed/29795047			
cov077	Favipiravir	C1=C(N=C(C(=O)N1)C(=O)N)F	4	Increases 7-day recovery rate in patients with COVID19	4	RNA transcription or replication	Patrick	https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1	https://www.sciencedirect.com/science/article/pii/S2095809920300631?via%3Dihub		
cov078	Remdesivir	CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4	3	Same Moa than Favipiravir. Effective in mice and cell lines. CLinical trials ongoing	4	RNA transcription or replication	Patrick	https://www.nature.com/articles/s41422-020-0282-0			
cov079	Camostat mesylate	O=C(C1=CC=C(NC(N)=N)C=C1)OC2=CC=C(CC(OCC(N(C)C)=O)=O)C=C2.CS(=O)(O)=O	2	Reduce SARS-Cov2 infection in Calu2 cells.	2	Viral entry	Adria	https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4			
cov080	E-64d	O=[C@@](N[C@H]([C@](NCCC(C)C)=O)CC(C)C)[C@H]1O[C@@H]1C(OCC)=O 	2	Reduce SARS-2-S infection in caco2 and 293T. No data for SARS-Cov2	2	Viral entry	Adria	https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4			
cov111	Ciclesonide	CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6	4	very small clinical trial with positive outcome	5	Immunomodulatory	Miquel/Gemma	https://www3.nhk.or.jp/nhkworld/en/news/20200303_20/			
cov112	Lopinavir	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O	4	HIV drug. Combination of Lopinavir, ritonavir and interferon beta is being evaluated in humans	3	Protease inhibitor	Victor	https://www.nature.com/articles/s41467-019-13940-6	https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1	https://www.medrxiv.org/content/10.1101/2020.03.28.20045955v1	https://www.medrxiv.org/content/10.1101/2020.03.22.20040832v2
cov116	Tocilizumab		4	inhibitor of the receptor of interleukin 6 (IL-6), a pro-inflammatory cytokine	5	Immunomodulatory	Victor	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext			
cov228	EIDD-2801	CC(C)C(=O)OC[C@H]2O[C@@H](n1ccc(NO)nc1=O)C(O)C2O	3	Clinical trials for Influenza, now considering for COVID	4	RNA transcription or replication	Edu	https://news.emory.edu/stories/2020/03/coronavirus_drive_ridgeback/index.html	https://www.ncbi.nlm.nih.gov/pubmed/31645453		
cov081	Beta-D-N4-hydroxycytidine		2	MoA: lethal mutagenesis, effective in vitro against SARS-Cov2 and in mice against SARS-CoV and MERS *BioArx	4	RNA transcription or replication	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.19.997890v1			
cov082	Niclosamide	C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O	2	MoA: inhibits SKP2 enzyme, tested in Vero cells *BioArx / Effect validated for Sars-CoV in 2003	1	Host factor	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov113	favipiravir	C1=C(N=C(C(=O)N1)C(=O)N)F	3	COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment	4	RNA transcription or replication	Martino	https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1			
cov199	BCX4430 (Immucillin-A)	O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O	2	inhibition of virus proliferation in cell culture assays using a Vero-E6 cell line infected with MERS-CoV	4	RNA transcription or replication	Isabelle	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937725/			
cov227	Aplidin	O=C([C@@H](NC([C@@H](C)C([C@@H](OC(C[C@H](O)[C@H](NC([C@@H](NC([C@H](N(C([C@H]1N(C(C(C)=O)=O)CCC1)=O)C)CC(C)C)=O)[C@@H](C)OC([C@H](CC2=CC=C(OC)C=C2)N3C)=O)=O)[C@@H](C)CC)=O)C(C)C)=O)=O)CC(C)C)N4[C@H](C3=O)CCC4	2	Pharmamar. Preclinical results on HCoV-229E, at nM range. Unpublished	1	Host factor	Edu	http://www.pmfarma.es/noticias/28280-pharmamar-anuncia-resultados-positivos-de-aplidin-contra-el-coronavirus-hcov-229e.html			
cov083	Ciclesonide	CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov084	Tilorone	CCN(CC)CCOC1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)OCCN(CC)CC	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	5	Immunomodulatory	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov085	Cyclosporine	CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	5	Immunomodulatory	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov086	Mefloquine	C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	2	Viral entry	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov087	Amodiaquine	CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	2	Viral entry	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov088	Proscillaridin	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov089	Digitoxin	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov090	Digoxin	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov091	Hexachlorophene	C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	3	Protease inhibitor	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov092	Hydroxyprogesterone caproate	CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov093	Salinomycin	CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov094	Ouabain	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov095	Cepharanthine	CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)C[C@@H]7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov096	Oxyclozanide	C1=C(C=C(C(=C1NC(=O)C2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl)Cl	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov097	Anidulafungin	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov098	Gilteritinib	CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	1	Host factor	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov099	Berbamine	CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov100	Tetrandine	CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov101	Abemaciclib	CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	1	Host factor	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov102	Ivacaftor	CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	1	Host factor	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov103	Bazedoxifene	CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov104	Eltrombopag	CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C	1	Preclinical evidence that diminishes SARS-Cov-2 viral load in Vero cells *BioArx	0	Unknown	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf+html			
cov105	Tenofovir diphosphate	C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)OP(=O)(O)OP(=O)(O)O	3	Inhibition of RdRp in polymerase extension experiment *BioArx	4	RNA transcription or replication	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html			
cov106	Sofosbuvir	C[C@@H](C(=O)OC(C)C)NP(=O)(OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3	3	Inhibition of RdRp in polymerase extension experiment *BioArx	4	RNA transcription or replication	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html			
cov107	3’-fluoro-3’-deoxythymidine triphosphate (Alovudine)	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)F	2	Inhibition of RdRp in polymerase extension experiment *BioArx	4	RNA transcription or replication	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html			
cov108	3’-azido-3’- deoxythymidine triphosphate (AZT-triP)	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)N=[N+]=[N-]	3	Inhibition of RdRp in polymerase extension experiment *BioArx	4	RNA transcription or replication	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.03.18.997585v1.full.pdf+html			
cov109	Atazanavir	CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC	3	None, computational (MoA: inhibitor 3CLp) *BioArx	3	Protease inhibitor	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.01.31.929547v1			
cov110	Efavirenz	C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F	3	None, computational (MoA: inhibitor 3CLp) *BioArx	4	RNA transcription or replication	Miquel/Gemma	https://www.biorxiv.org/content/10.1101/2020.01.31.929547v1			
cov114	arbidol	CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3	3	COVID-19 patients untreated with antiviral previously, favipiravir can be considered as a preferred treatment	2	Viral entry	Martino	https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1			
cov115	Baricitinib	CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3	1	affinity AAK-1 binding drug	5	Immunomodulatory	Victor	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30304-4/fulltext			
cov117	Velpatasvir	CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC	3	NS5A inhibtors in HCV found through Virtual Screening	4	RNA transcription or replication	Adria	https://f1000research.com/articles/9-129/v1			
cov118	Ledipasvir	CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC	3	NS5A inhibtors in HCV found through Virtual Screening	4	RNA transcription or replication	Adria	https://f1000research.com/articles/9-129/v1			
cov119	Praziquantel	C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/2			
cov120	Cinacalcet	CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/3			
cov121	Procainamide	CCN(CC)CCNC(=O)C1=CC=C(C=C1)N	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/4			
cov122	Terbinafine	CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/5			
cov123	Pethidine	O=C(C1(CCN(CC1)C)C2=CC=CC=C2)OCC	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/6			
cov124	Labetalol	CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/7			
cov125	Tetrahydrozoline	C1CC(C2=CC=CC=C2C1)C3=NCCN3	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/8			
cov126	Ticlopidine	C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/9			
cov127	Ethoheptazine	CCOC(=O)C1(CCCN(C)CC1)C1=CC=CC=C1	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/10			
cov128	Levamisole	C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/11			
cov129	Amitriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/12			
cov130	Naphazoline	C1CN=C(N1)CC2=CC=CC3=CC=CC=C32	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/13			
cov131	Formoterol	CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/14			
cov132	Benzylpenicillin	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)Cc3ccccc3)C(=O)O)C	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/15			
cov133	Chloroquine	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/16			
cov134	Chlorothiazide	C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2	1	Papain-like protease inhibitors found by docking using Homology modeling from SARS CoV. Drugs found through VS of FDA aproved drugs.	3	Protease inhibitor	Adria	https://chemrxiv.org/articles/Potential_Inhibitors_Against_Papain-like_Protease_of_Novel_Coronavirus_COVID-19_from_FDA_Approved_Drugs/11860011/17			
cov135	Indinavir	CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov136	Saquinavir	CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov137	Lopinavir	CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov138	Carfilzomib	CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3)NC(=O)CN4CCOCC4	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	1	Host factor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov139	Remdesivir	CCC(COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@@]([C@@H]([C@@H]1O)O)(C#N)c1ccc2n1ncnc2N)C)CC	4	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	4	RNA transcription or replication	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov140	Atazanavir	CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)NC(=O)OC)O)NC(=O)OC	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov141	Darunavir	CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov142	Tipranavir	CCC[C@]1(CC(/O)=C(\C(=O)O1)[C@H](CC)c3cccc(NS(=O)(=O)c2ccc(cn2)C(F)(F)F)c3)CCc4ccccc4	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov143	Fosamprenavir	CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov144	Enzaplatovir	O=C1C2=CC=CN2C[C@@]3(C4=CC=C(C)N=C4)N1CCN3C(C5=CON=C5C)=O	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	2	Viral entry	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov145	Presatovir	CC1=CN2C(=CC(=N2)C3CCCCN3C(=O)C4=C(C=CC(=C4)Cl)NS(=O)(=O)C)N=C1N5CCC(C5)N	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	2	Viral entry	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov146	Abacavir	C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	4	RNA transcription or replication	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov147	Bortezomib	B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	1	Host factor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov148	Elvitegravir	CC(C)C(CO)N1C=C(C(=O)C2=C1C=C(C(=C2)CC3=C(C(=CC=C3)Cl)F)OC)C(=O)O	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov149	Maribavir	CC(C)NC1=NC2=CC(=C(C=C2N1C3C(C(C(O3)CO)O)O)Cl)Cl	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov150	Raltegravir	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov151	Montelukast	CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O	3	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	5	Immunomodulatory	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov152	Deoxyrhapontin	COC1=CC=C(C=C1)C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov153	Polydatin	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov154	Chalcone	C1=CC=C(C=C1)C=CC(=O)C2=CC=CC=C2	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov155	Disulfiram	CCN(CC)C(=S)SSC(=S)N(CC)CC	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov156	Carmofur	CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	4	RNA transcription or replication	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov157	Shikonin	CC(=CCC(C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov158	Ebselen	C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov159	Tideglusib	C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov160	PX-12	CCC(C)SSC1=NC=CN1	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov161	TDZD-8	CN1SC(N(C1=O)CC2=CC=CC=C2)=O	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	1	Host factor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov162	Cyclosporin A	CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	0	Unknown	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov163	Cinanserin	CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C2=CC=CC=C2	1	Mpro (Viral Main proteinase) inhibitors found though VS + Enzimolgy tests 	3	Protease inhibitor	Adria	https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf/-char/en			
cov164	JQ1	O=C(OC(C)(C)C)C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov165	RVX-208	O=C1C2=C(OC)C=C(OC)C=C2NC(C3=CC(C)=C(OCCO)C(C)=C3)=N1	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov166	Silmitasertib	C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov167	TMCB	CN(C)C1=NC2=C(N1CC(=O)O)C(=C(C(=C2Br)Br)Br)Br	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov168	Apicidin	CCC(C)C1C(=O)N2CCCCC2C(=O)NC(C(=O)NC(C(=O)N1)CC3=CN(C4=CC=CC=C43)OC)CCCCCC(=O)CC	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov169	Valproic Acid	CCCC(CCC)C(=O)O	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov170	Bafilomycin A1	CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C(C)C)C)O)O)O)OC)C	1	Drugs from Sars-Cov-2-Human PPI map	2	Viral entry	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov171	E-52862	CC1=CC(OCCN2CCOCC2)=NN1C1=CC=C2C=CC=CC2=C1	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov172	PD-144418	CCCN1CCC=C(C1)C2=CC(=NO2)C3=CC=C(C=C3)C	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov173	RS-PPC	COC(=O)C1(CC1CN2CCC(O)(CC2)c3ccccc3)c4ccc(C)cc4	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov174	PB28	COc1c(CCCC2CCCN3CCN(C4CCCCC4)CC3)c2ccc1	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov175	Haloperidol 	c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov176	Entacapone	CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov177	Indomethacin 	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O	1	Drugs from Sars-Cov-2-Human PPI map	5	Immunomodulatory	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov178	Metformin	CN(C)C(=N)N=C(N)N	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov179	Ponatinib 	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov180	H-89	O=S(C2=CC=CC1=CN=CC=C12)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O.Cl.Cl	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov181	Merimepodib	COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov182	Migalastat	C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov183	Mycophenolic acid	CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O	1	Drugs from Sars-Cov-2-Human PPI map	5	Immunomodulatory	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov184	Ribavirin	C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N	1	Drugs from Sars-Cov-2-Human PPI map	4	RNA transcription or replication	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov185	XL413	ClC1=CC=C2C(C(N=[C@@]([C@H]4NCCC4)NC3=O)=C3O2)=C1.Cl	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov186	CCT 365623	CS(=O)(=O)C=1C=C(C=C(C1)C1=CC=CC=C1)S(=O)(=O)C1=CC=C(S1)CN	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov187	Midostaurin	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov188	Ruxolitinib	C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov189	ZINC1775962367		1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov190	ZINC4326719		1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov191	ZINC451 1851		1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov192	ZINC95559591		1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov193	AC-55541	O=C2C1=CC=CC=C1C(C(NC(C3=CC=CC=C3)=O)C(N/N=C(C)/C4=CC=CC(Br)=C4)=O)=NN2	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov194	AZ8838	O[C@H](C1=CC=C(F)C=C1CCC)C2=NC=CN2	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov195	Daunorubicin	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov196	GB 110		1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov197	S-verapamil	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov198	AZ3451	C[C@H](N1C2=CC=C(C(NC3=CC=C(C#N)C=C3)=O)C=C2N=C1C4=C(C=C5OCOC5=C4)Br)C6CCCCC6	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov200	ABBV-744	CC(O)(C)C1=CC(C(C2=C3NC(C(NCC)=O)=C2)=CN(C)C3=O)=C(OC4=C(C)C=C(F)C=C4C)C=C1	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov201	dBET6	O=C(NCCCCCCCCNC(COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)=O)C[C@H]4C5=NN=C(C)N5C6=C(C(C)=C(C)S6)C(C7=CC=C(Cl)C=C7)=N4	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov202	MZ1	CC1=NN=C2[C@H](CC(NCCOCCOCCOCC(N[C@@H](C(C)(C)C)C(N3[C@H](C(NCC4=CC=C(C5=C(C)N=CS5)C=C4)=O)C[C@@H](O)C3)=O)=O)=O)N=C(C6=CC=C(Cl)C=C6)C7=C(SC(C)=C7C)N21	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov203	CPI-0610	CC1=NOC2=C1C3=CC=CC=C3C(=N[C@H]2CC(=O)N)C4=CC=C(C=C4)Cl	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov204	Sapanisertib	CC(C)N1C2=NC=NC(=C2C(=N1)C3=CC4=C(C=C3)OC(=N4)N)N	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov205	Rapamycin	O[C@@H]1CC[C@H](C[C@H]1OC)C[C@@H](C)[C@@H]4CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N3CCCC[C@H]3C(=O)O4	1	Drugs from Sars-Cov-2-Human PPI map	5	Immunomodulatory	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov206	Zotatifin	CN(C)C[C@@H]1[C@H]([C@]2([C@@]([C@@H]1O)(C3=C(N=C(C=C3O2)OC)OC)O)C4=CC=C(C=C4)C#N)C5=CC=CC=C5	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov207	Verdinexor	C1=CC=NC(=C1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov209	Dabrafenib	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov210	WDB002		1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov211	Sanglifehrin A	CC[C@H]1C[C@@H]([C@@]2([C@H]([C@H]([C@H]([C@@H](O2)C[C@@H]([C@@H](C)CC/C=C/C=C(\C)/[C@@H]3C/C=C/C=C/[C@@H]([C@@H]([C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H](N4)C(=O)O3)CC5=CC(=CC=C5)O)C(C)C)CCC(=O)C)O)C)O)O)C)O)C)NC1=O)C	1	Drugs from Sars-Cov-2-Human PPI map	5	Immunomodulatory	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov212	FK-506	C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC	1	Drugs from Sars-Cov-2-Human PPI map	5	Immunomodulatory	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov213	Pevonedistat	C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov214	Ternatin 4	C1=CC(=CC=C1/C=C/C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC=C(C=C3)/C=C/C(=O)OC[C@@H]4[C@H]([C@@H]([C@H]([C@@H](O4)OC5=CC(=CC(=C5O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)COC(=O)/C=C/C7=CC=C(C=C7)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)COC(=O)/C=C/C9=CC=C(C=C9)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O)O)O)O)O)O)C1=[O+]C2=CC(=CC(=C2C=C1O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC(=O)CC(=O)O)O)O)O)O)O)O)O)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov215	4E2RCat	O=C(O)C1=CC(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)=CC=C1Cl	1	Drugs from Sars-Cov-2-Human PPI map	4	RNA transcription or replication	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf	https://www.ncbi.nlm.nih.gov/pubmed/?term=Blocking+eIF4E%3AeIF4G+interaction+as+a+strategy+to+impair+coronavirus+replication		
cov216	Tomivosertib	CC1=C2C(=O)NC3(N2C(=O)C(=C1)NC4=NC=NC(=C4)N)CCCCC3	1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov217	Compound 2		1	Drugs from Sars-Cov-2-Human PPI map	4	RNA transcription or replication	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov218	Compound 10		1	Drugs from Sars-Cov-2-Human PPI map	4	RNA transcription or replication	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov219	PD3061		1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov220	IHVR-19029		1	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov221	Captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O	1	Drugs from Sars-Cov-2-Human PPI map	2	Viral entry	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov222	Lisinopril	C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O	1	Drugs from Sars-Cov-2-Human PPI map	2	Viral entry	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov223	Camostat	CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N	1	Drugs from Sars-Cov-2-Human PPI map	2	Viral entry	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov224	Chloramphenicol	C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov225	Tigecycline	CC(C)(C)NCC(=O)NC1=CC(=C2C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C(C2=C1O)O)O)O)C(=O)N)N(C)C)N(C)C	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov226	Linezolid	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F	1	Drugs from Sars-Cov-2-Human PPI map	0	Unknown	Victor	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf			
cov229	Rintatolimod	O=P(O)(O)OC[C@H]3O[C@@H](n1c2N\C=N/C(=O)c2nc1)[C@H](O)[C@@H]3O.O=C1/N=C(/N)\C=C/N1[C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O.O=C/1NC(=O)N(\C=C\1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP(=O)(O)O	1	Under investigation for possible prophylactic/early-onset therapeutic against COVID-19	5	Immunomodulatory	Adria	https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/			
cov223	Brilacidin	C1CNC[C@@H]1OC2=C(C=C(C=C2NC(=O)C3=CC(=NC=N3)C(=O)NC4=CC(=CC(=C4O[C@@H]5CCNC5)NC(=O)CCCCNC(=N)N)C(F)(F)F)C(F)(F)F)NC(=O)CCCCNC(=N)N	1	Mimic the human innate immune system and a mechanism of action, disrupting the membrane of pathogens (mainly bacterial). Remains to be tested.	0	Unknown	Adria	https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/			
cov224	Theaflavin	c1c(cc(=O)c(c2c1c(cc(c2O)O)[C@@H]3[C@@H](Cc4c(cc(cc4O3)O)O)O)O)[C@@H]5[C@@H](Cc6c(cc(cc6O5)O)O)O	1	Inhibits the Sars-Cov-2 receptor binding domain (RBD) in the distal part of S1 subunit, according to docking analysis	2	Viral entry	Adria	https://www.biorxiv.org/content/biorxiv/early/2020/03/26/2020.03.26.009803.full.pdf?%3Fcollection=			
cov225	Danoprevir	CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\[C@@H]2C[C@]2(NC(=O)[C@@H]3C[C@H](CN3C1=O)OC(=O)N4CC5=C(C4)C(=CC=C5)F)C(=O)NS(=O)(=O)C6CC6	4	Potent HCV protease (NS3/4A) inhibitor (IC50 = 0.29 nM), which was approved in China since 2018 to treat chronic hepatitis C patients	3	Protease inhibitor	Victor	https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1			
cov226	Hydroxychloroquine	CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO	4	Anti SARS-CoV and MERS-CoV in vitro. Clinical Trials in China at France	2	Viral entry	Victor	https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v1	https://www.biorxiv.org/content/10.1101/2020.03.29.014407v1	https://www.medrxiv.org/content/10.1101/2020.03.24.20042366v1.article-metrics	
cov227	Migalastat	C1[C@@H]([C@H]([C@H]([C@H](N1)CO)O)O)O	3	Drugs from Sars-Cov-2-Human PPI map	1	Host factor	Victor/Isa	https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1.full.pdf	https://www.ncbi.nlm.nih.gov/pubmed/30723321		
cov223	Azithromycin	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O	2	Azithromycin confers in vitro effects on intracellular organelles similar to the effects of chloroquine	2	Viral entry	Victor	https://www.biorxiv.org/content/10.1101/2020.03.29.008631v1			
cov224	Baloxavir marboxil	COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F	4	Antiviral activity against influenza and as potential treatment options for COVID-19	4	RNA transcription or replication	Victor	https://www.nature.com/articles/d41587-020-00003-1			
cov225	Triazavirin	CSc1[nH]n2c(=O)c(nnc2n1)[N+](=O)[O-]	4	Non-nucleoside antiviral drug; effective against tick-borne encephalitis virus and forest-spring encephalitis virus	4	RNA transcription or replication	Victor	http://www.chictr.org.cn/showprojen.aspx?proj=49723			
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
cov224											
cov225											
cov226											
cov229											
cov223											
